Table 2.
Sample size by molecular subtype status and sex.
| Molecular subtype | Men | Women | Total |
|---|---|---|---|
| MS | |||
| MSI high | 505 | 660 | 1165 |
| non-MSI-high | 3520 | 2985 | 6505 |
| CIMP | |||
| CIMP-high | 383 | 617 | 1000 |
| CIMP-low/negative | 2951 | 2311 | 5262 |
| KRAS | |||
| Mutation | 1147 | 1018 | 2165 |
| Wildtype | 2367 | 2107 | 4474 |
| BRAF | |||
| Mutation | 317 | 555 | 872 |
| Wildtype | 3526 | 2900 | 6426 |
| Jass groups | |||
| Type 1 | 84 | 258 | 342 |
| Type 2 | 51 | 97 | 148 |
| Type 3 | 739 | 682 | 1421 |
| Type 4 | 1446 | 1023 | 2469 |
| Type 5 | 104 | 83 | 187 |
| Controls | 5180 | 5292 | 10,472 |
CIMP, CpG island methylator phenotype; MSI, microsatellite instability.
Type 1 (MSI-high, CIMP-high, BRAF-mutated, KRAS-wildtype).
Type 2 (non-MSI-high, CIMP-high, BRAF-mutated, KRAS-wildtype).
Type 3 (non-MSI-high, CIMP-low/negative, BRAF-wildtype, KRAS-mutated).
Type 4 (non-MSI-high, CIMP-low/negative, BRAF-wildtype, KRAS-wildtype).
Type 5 (MSI-high, CIMP-low/negative, BRAF-wildtype, KRAS-wildtype).